WO2021020841A1 - Composition pour la prévention ou le traitement d'une maladie hépatique métabolique - Google Patents

Composition pour la prévention ou le traitement d'une maladie hépatique métabolique Download PDF

Info

Publication number
WO2021020841A1
WO2021020841A1 PCT/KR2020/009862 KR2020009862W WO2021020841A1 WO 2021020841 A1 WO2021020841 A1 WO 2021020841A1 KR 2020009862 W KR2020009862 W KR 2020009862W WO 2021020841 A1 WO2021020841 A1 WO 2021020841A1
Authority
WO
WIPO (PCT)
Prior art keywords
ulixertinib
liver disease
composition
pharmaceutical composition
alcoholic fatty
Prior art date
Application number
PCT/KR2020/009862
Other languages
English (en)
Inventor
Daehee HAN
Hee Jung Koo
Jinhan Kim
Sang Ok Song
So Jeong Yun
Original Assignee
Standigm Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Standigm Inc. filed Critical Standigm Inc.
Publication of WO2021020841A1 publication Critical patent/WO2021020841A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating metabolic liver disease, comprising ulixertinib. More specifically, the present invention relates to a composition for preventing or treating non-alcoholic fatty liver disease (NAFLD), comprising ulixertinib.
  • NAFLD non-alcoholic fatty liver disease
  • Fatty liver diseases has two main types, one related to excessive alcohol consumption and the other to metabolic dysregulation.
  • the fatty liver disease resulting from metabolic dysregulation can be metabolic liver disease, which comprises hepatic steatosis, steatohepatitis, or liver fibrosis.
  • Non-alcoholic fatty liver disease is the metabolic liver disease described above, and is a disease caused by fat accumulation in the liver that is not associated with alcohol consumption.
  • Non-alcoholic fatty liver diseases refers to the group of diseases including simple steatosis, in which only the excessive accumulation of fat in hepatic cells is present, and non-alcoholic steatohepatitis (NASH), which is accompanied by necrosis, inflammation, and fibrosis of hepatic cells (Brunt EM, Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 21, 3-16, 2001).
  • Non-alcoholic steatohepatitis occurs during the exacerbation process of non-alcoholic fatty liver disease (NAFLD).
  • NASH non-alcoholic fatty liver disease
  • inflammatory cytokines are secreted where the debris from destroyed hepatic cells undergoes phagocytosis by Kupffer cells and macrophages.
  • the secreted cytokines activate hepatic stellate cells, which adjust the blood flow between hepatic sinusoid endothelial cells and hepatic cells, to synthesize and secrete connective tissue components including collagen, thereby causing the development of fibrosis.
  • NASH non-alcoholic steatohepatitis
  • ulixertinib is an inhibitor of extracellular signal-regulated kinase 1 (ERK1) and extracellular signal-regulated kinase 2 (ERK2), which prevents the activation of an ERK-mediated signaling pathway by inhibiting both ERK1 and ERK2. Accordingly, the potential anticancer activity of ulixertinib by inhibiting the proliferation and survival of ERK-dependent tumor cells has been studied (Germann et al., 2015). However, there have been no reports on any correlation between ulixertinib and metabolic liver disease, specifically, non-alcoholic fatty liver disease.
  • ERK1 extracellular signal-regulated kinase 1
  • ERK2 extracellular signal-regulated kinase 2
  • the present inventors have made intensive efforts to develop a composition for treating or preventing metabolic liver disease, particularly, non-alcoholic fatty liver disease.
  • ulixertinib which was selected through artificial intelligence (AI) deep learning technology, alleviates steatosis, inflammation, or ballooning, and reduces the area of fibrosis due to inflammation, thereby completing the present invention.
  • AI artificial intelligence
  • One object of the present invention is to provide a pharmaceutical composition for preventing or treating metabolic liver disease, comprising ulixertinib or a pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease (NAFLD), comprising ulixertinib or a pharmaceutically acceptable salt thereof.
  • NAFLD non-alcoholic fatty liver disease
  • Still another object of the present invention is to provide a method for treating metabolic liver disease, comprising administering the pharmaceutical composition to a subject.
  • composition of the present invention which comprises ulixertinib, reduces steatosis, inflammation, or ballooning in liver tissue where non-alcoholic fatty liver has been induced; reduces the level of fibrosis of inflammation induced by non-alcoholic fatty liver; and reduces the weight of a liver that has increased due to non-alcoholic fatty liver disease. Accordingly, the composition of the present invention can be effectively used for the prevention or treatment of metabolic liver disease, including non-alcoholic fatty liver disease.
  • FIG. 1 shows liver fragments stained with hematoxylin and eosin (H&E).
  • FIG. 2 is a figure quantifying steatosis scores (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 3 is a figure quantifying inflammation scores (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 4 is a figure quantifying ballooning scores (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 5 is a figure quantifying NAFLD activity scores (NAS). P values were measured according to the Bonferroni Multiple Comparison Test (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 6 shows liver fragments stained with sirius red.
  • FIG. 7 is a figure quantifying a percentage of a fibrosis area due to inflammation and a sirius red-positive area. P values were measured according to the Bonferroni Multiple Comparison Test (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 8 shows liver fragments stained with H&E.
  • FIG. 9 is a figure quantifying steatosis scores (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 10 is a figure quantifying inflammation scores (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 11 is a figure quantifying ballooning scores (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 12 is a figure quantifying NAFLD activity scores. P values were measured according to the Bonferroni Multiple Comparison Test (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 13 shows liver fragments stained with sirius red.
  • FIG. 14 is a figure quantifying a percentage of a fibrosis area due to inflammation and a sirius red-positive area. P values were measured according to the Bonferroni Multiple Comparison Test (V: vehicle, T: telmisartan, U: ulixertinib).
  • FIG. 15 shows the body weight, liver weight, and liver-to-body weight ratio of a mouse from each group. P values were measured according to the Bonferroni Multiple Comparison Test (V: vehicle, T: telmisartan, U: ulixertinib).
  • An aspect of the present invention for resolving the technical problem above provides a pharmaceutical composition for preventing or treating metabolic liver disease, comprising ulixertinib or a pharmaceutically acceptable salt thereof.
  • the term “ulixertinib” refers to the compound 4- ⁇ 5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl ⁇ -N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide, which is an inhibitor of extracellular signal-regulated kinase 1 (ERK1) and extracellular signal-regulated kinase 2 (ERK2). That is, ulixertinib prevents the activation of an ERK-mediated signaling pathway by inhibiting both ERK1 and ERK2. Accordingly, it has been known that ulixertinib has a potential activity as an anticancer drug by inhibiting the proliferation and survival of ERK-dependent tumor cells.
  • the ulixertinib has an effect of alleviating steatosis, inflammation, or ballooning in liver tissue where non-alcoholic fatty liver is has been induced, and an effect of reducing fibrosis due to inflammation induced by the disease above, and thus, the present invention is significant in discovering for the first time that the ulixertinib can be used in treating metabolic liver disease.
  • the ulixertinib may be a chemical compound represented by Chemical Formula I below.
  • the ulixertinib may be commercially available through a synthetic method known in the art, but is not limited thereto.
  • the term "pharmaceutically acceptable salt” refers to any organic or inorganic addition salt of the compound above at a concentration having relatively nontoxic and harmless effective actions in a subject, where side effects attributed to the salt do not deteriorate the beneficial efficacy of the compound.
  • the compound may be used alone or in combination with another pharmaceutically active compound or in an aggregate.
  • the pharmaceutically acceptable salt of ulixertinib refers to a salt prepared according a conventional method known in the art, and such preparation method is known to one of ordinary skill in the art.
  • the pharmaceutically acceptable salt may include salts which are induced from the following inorganic acids, organic acids, and bases, which are pharmacologically or physiologically acceptable, but the pharmaceutically acceptable salt is not limited thereto.
  • Acid addition salts may be prepared using a conventional method such as dissolving a compound in an excess aqueous acid solution, and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone, or acetonitrile.
  • a water-miscible organic solvent such as methanol, ethanol, acetone, or acetonitrile.
  • An equimolar compound and an acid or alcohol in water e.g., glycol monomethyl ether
  • the free acid may include an inorganic acid or an organic acid.
  • the inorganic acid may include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc.
  • the organic acid may include methanesulfonic acid, p -toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc.
  • the inorganic acid and organic acid are not limited thereto.
  • a pharmaceutically acceptable metal salt may be prepared using a base.
  • An alkali metal salt or alkaline earth metal salt is obtained by, for example, dissolving a compound in an excess alkali metal hydroxide solution or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate.
  • preparation of a sodium, potassium, or calcium salt as the metal salt is pharmaceutically suitable, but the metal salt is not limited thereto.
  • a corresponding silver salt may be obtained by reacting the alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).
  • the pharmaceutical composition of the present invention which comprises ulixertinib or a pharmaceutically acceptable salt thereof, may further include a suitable carrier, excipient, or diluent, which is conventionally used in preparation of a pharmaceutical composition.
  • the carrier may also include a non-naturally occurring carrier, but is not limited thereto.
  • Carriers, excipients, or diluents which can be used in the present invention may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil, etc.
  • the pharmaceutical composition according to the present invention may be used by being formulated into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosol, etc., external solutions, suppositories, and sterile injectable solution, according to a conventional method for each thereof.
  • the pharmaceutical composition may be formulated in combination with a commonly-used diluent or excipient such as a filler, extender, binder, humectant, disintegrating agent, surfactant, etc.
  • Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, etc ., and these solid formulations may be prepared by mixing with at least one excipient, e.g., starch, calcium carbonate, sucrose or lactose, gelatin, etc .
  • a lubricant such as magnesium stearate, talc, etc .
  • Liquid formulations for oral administration may include suspensions, oral solutions, emulsions, syrups, etc ., and in addition to a simple diluent such as water or liquid paraffin, various excipients such as humectants, sweeteners, flavoring agents, preservatives, etc. , may be used in the liquid formulations.
  • the term "metabolic liver disease” refers to a disease caused by metabolic dysregulation in the liver that is not associated with alcohol consumption.
  • the metabolic liver disease may be non-alcoholic fatty liver disease (NAFLD), but is not limited thereto.
  • An aspect of the present invention provides a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, comprising ulixertinib or a pharmaceutically acceptable salt thereof.
  • non-alcoholic fatty liver disease refers to a disease caused by fat accumulation in the liver which is not associated with alcohol consumption.
  • the non-alcoholic fatty liver disease may include liver triglyceride accumulation, simple steatosis, non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and NAFLD-related liver fibrosis or hepatocirrhosis, which is caused by advancement of the diseases above.
  • the non-alcoholic fatty liver disease may progress into non-alcoholic steatohepatitis or non-alcoholic steatohepatitis accompanied by fibrosis.
  • non-alcoholic steatohepatitis refers to a disease which occurs during the exacerbation process of non-alcoholic fatty liver disease (NAFLD), and in which triglyceride accumulates in the liver and the increase of Kupffer cells and the activation of phagocytes proceed in the fatty state. Subsequently, the oxidation of hepatocellular mitochondria occurs, causing inflammation and fibrosis.
  • the main symptoms of the disease may include steatosis, inflammation, or ballooning, and may be accompanied by fibrosis of the liver tissue.
  • the "steatosis” refers to a phenomenon in which lipids accumulate due to abnormalities in lipid metabolism.
  • the "inflammation” refers to the degree of lobular inflammation in the liver.
  • the “ballooning” refers to ballooning of hepatic cells or degeneration caused by swelling of hepatic cells.
  • the “fibrosis” refers to a phenomenon in which a part of the tissue is hardened.
  • the pharmaceutical composition of the present invention which comprises ulixertinib, may reduce steatosis, inflammation, or ballooning, which are the symptoms of non-alcoholic fatty liver disease among metabolic liver diseases, or may reduce the fibrosis of inflammation, but is not limited thereto.
  • NAFLD activity score (NAS).
  • the composition reduces steatosis, inflammation, and ballooning (FIGS. 2 to 5, and 9 to 12). Specifically, it was confirmed that when the ulixertinib of the present invention was intraperitoneally administered at a dose of 5 mg/kg, the steatosis score reduced to an average of 0.14 as compared to that of the vehicle administration group (an average of 0.75), which is the negative control group (FIG. 2). In particular, it was shown that when the composition of the present invention was administered, there were five subjects with a ballooning score of 0 (i.e., evaluated as not having ballooned cells) (FIG. 4).
  • the composition of the present invention exhibits a significant effect in reducing ballooning. Accordingly, it was shown that the NAFLD activity score, which reflects ballooning, was also reduced as compared to that of the vehicle administration group (FIG. 5).
  • the ulixertinib of the present invention exhibited an effect of reducing the NAFLD activity score as compared to that of the vehicle administration group.
  • the composition reduced the fibrosis of inflammation induced by non-alcoholic steatohepatitis (FIGS. 6, 7, 13, and 14). Specifically, the fibrosis area score of the vehicle administration group was 0.73 on average, while that of the telmisartan administration group (i.e., positive control group) was 0.35 on average, and that of the ulixertinib administration group was 0.34 on average similar to that of the telmisartan administration group.
  • the fibrosis area score was reduced to 0.5 as compared to that of the vehicle administration group (0.7 on average), and this score was similar to that of the telmisartan administration group (0.4 on average) (FIG. 14).
  • the ulixertinib of the present invention showed an effect of reducing the fibrosis area to a level similar to that of the positive control group (i.e., telmisartan).
  • the pharmaceutical composition of the present invention which comprises ulixertinib, has an effect of preventing or treating metabolic liver disease, specifically, non-alcoholic fatty liver disease.
  • prevention refers to any activity that inhibits or delays the occurrence, spread, or recurrence of a subject disease by administration of the pharmaceutical composition
  • treatment refers to any activity associated with the amelioration or advantageous changes in symptoms of a subject disease by administration of the pharmaceutical composition.
  • the treatment may be achieve reduction or alleviation of signs of metabolic liver disease, specifically, non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis, reduction of the severity of the disease, delay or slowing of the disease, palliation or stabilization of the disease condition, or other advantageous results, but the treatment is not limited thereto.
  • Still another aspect of the present invention provides a method for preventing or treating metabolic liver disease including non-alcoholic fatty liver disease, comprising administrating the pharmaceutical composition to a subject.
  • the term "subject” refers to all animals including humans that have or may develop a subject disease, and by administering the pharmaceutical composition of the present invention to a subject suspected of having or suffering from metabolic liver disease, the disease may be effectively treated or prevented.
  • the pharmaceutical composition of the present invention may be applied to any subject without particular limitation as long as the pharmaceutical composition is used for preventing or treating metabolic liver disease in a subject.
  • any animal such as monkeys, dogs, cats, rabbits, marmots, rats, mice, cows, sheep, pigs, goats, etc., birds, fish, etc. may be used a subject.
  • the term "administration" refers to the introduction of a prescribed substance to a patient by any suitable method, and the administration route of the composition may be any general route as long as a drug reaches a target tissue.
  • the administration may be intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, rectal administration, etc., but is not limited thereto.
  • a composition for an oral administration since peptides are digested, it would be preferable to formulate a composition for an oral administration to be coated with an active agent, or to be protected from degradation in the stomach.
  • a pharmaceutical composition may be administered by any device which enables an active substance to travel to a target cell.
  • the pharmaceutical composition of the present invention may include a pharmaceutically effective amount of a chemical compound, or an isomer or salt thereof.
  • pharmaceutically effective amount refers to an amount sufficient for the treatment of a disease at a reasonable benefit/risk ratio applicable to a medical treatment. In general, for adults (60 kg), an amount of 0.001 mg/day to 10,000 mg/day, specifically, an amount of 0.01 mg/day to 1,000 mg/day, more specifically, an amount of 0.05 mg/day to 500 mg/day, and even more specifically, an amount of 0.1 mg/day to 50 mg/day, may be administered once or several times per day.
  • a NASH mouse was orally administered with a vehicle supplemented with ulixertinib at a dose of 4 mg/kg (in a volume of 10 mL/kg) once per day from 6 weeks to 9 weeks of age.
  • a specific therapeutically effective amount may be differently applied to a certain patient depending on the type and degree of a response to be achieved, a specific composition including whether other formulations are used in some cases, a patient's age, body weight, general health condition, sex, diet, administration time, administration routes, secretion rate of a composition, duration of treatment, various factors including a drug(s) to be used or simultaneously used in combination with the specific composition, and similar factors well-known in the medical field.
  • the therapeutically effective amount may be determined by one of ordinary skill in the art through a conventional dose determination test in the medical field with a set of symptoms provided.
  • the frequency of administration of the pharmaceutical composition of the present invention is not particularly limited, but may be once per day or several times in divided doses.
  • the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent, or in combination with other therapeutic agent(s).
  • the pharmaceutical composition of the present invention may be administered in combination with a conventional therapeutic agent(s) sequentially or simultaneously.
  • the pharmaceutical composition may be administered in a single dose or multiple doses. It is important to administer an amount to obtain the maximum effect with a minimum amount without adverse effects considering all of the factors described above, and these factors can be easily determined by one of ordinary skill in the art.
  • the pharmaceutical composition of the present invention may be used alone or in combination with an operation, hormone therapy, drug therapy, and a method of using a biological response modifier.
  • the pharmaceutical composition according to the present invention may be administered in combination with one or more additional drugs which are conventionally used in the treatment of metabolic liver disease.
  • the composition may be administered in combination with a therapeutic agent for non-alcoholic fatty liver disease.
  • the composition may be administered in combination with a therapeutic agent for non-alcoholic steatohepatitis, but is not limited thereto.
  • the pharmaceutical composition according to the present invention When the pharmaceutical composition according to the present invention is administered for the purpose of treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis, the pharmaceutical composition may be administered in combination with one or more components and/or drugs effective in the treatment or prevention of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
  • the ulixertinib of the present invention or the pharmaceutically acceptable salt thereof in combination with the one or more additional drugs may be administered simultaneously, sequentially, or in reverse order.
  • the combination administration may be simultaneous administration at a suitable effective amount, or may be simultaneous, sequential, or reverse order administration after storage in separate containers.
  • Examples of the components and/or drugs effective in the treatment or prevention of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis may include thiazolidinediones (TZDs), vitamin E, metformin, statins, ursodeoxycholic acid (UDCA), polyunsaturated fatty acids such as omega 3, etc.
  • TZDs thiazolidinediones
  • vitamin E vitamin E
  • metformin statins
  • statins ursodeoxycholic acid (UDCA)
  • UDCA ursodeoxycholic acid
  • polyunsaturated fatty acids such as omega 3, etc.
  • angiotensin receptor blockers pentoxifylline, glucagon-like peptide 1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium/glucose cotransporter 2 (SGLT2) inhibitors, obeticholic acid (OCA), elafibranor, telmisartan, MGL-3196, Aramchol, Cenicriviroc, brieflysertib, Simtuzumab, etc. , but the examples thereof are not particularly limited thereto. Any components and/or drugs known in the art may be used without limitation as long as they are effective in the treatment or prevention of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
  • Still another aspect of the present invention provides a food composition for preventing or ameliorating metabolic liver disease, comprising ulixertinib or a sitologically acceptable salt thereof.
  • the term “amelioration” refers to any activity that improves or benefits the symptoms of a subject suspected of having or suffering from a subject disease by using a composition comprising ulixertinib or a sitologically acceptable salt thereof.
  • the food composition according to the present invention may include a formulation such as pills, powders, granules, infusions, tablets, capsules, or liquids, etc.
  • Foods to which the composition of the present invention can be added may include, for example, various kinds of foods such as beverages, gums, teas, vitamin complexes, health supplement food, etc.
  • Ingredients of the food composition of the present invention may include other ingredients without limitation in addition to ulixertinib, which is an essential ingredient, and may contain various herbal medicine extracts, food supplement additives, or natural carbohydrates, etc. as additional ingredients, like common foods.
  • the food supplement additive may include a common food supplement additive used in this field, for example, flavoring agents, aromatics, coloring agents, fillers, stabilizers, etc.
  • Examples of the natural carbohydrate may include common saccharides such as monosaccharides (e.g., glucose, fructose, etc. ); disaccharides ( e.g., maltose, sucrose, etc. ); and polysaccharides ( e.g., dextrin, cyclodextrin, etc .), and sugar alcohols such as xylitol, sorbitol, erythritol, etc.
  • natural flavoring agents e.g., rebaudioside A, glycyrrhizine, etc.
  • synthetic flavoring agents saccharides
  • saccharides such as monosaccharides (e.g., glucose, fructose, etc. ); disaccharides (e.g., maltose, sucrose, etc. ); and polysaccharides ( e.g., dextrin, cyclodextrin, etc .), and sugar alcohols such as xylitol
  • the food composition of the present invention may contain various nutritional supplements, vitamins, minerals (electrolytes), aromatics including synthetic aromatics, natural aromatics, etc., coloring agents, and fillers (cheese, chocolate, etc. ), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, etc.
  • the food composition of the present invention may contain natural fruit juices and fruit flesh for the preparation of fruit juices and vegetable drinks. These ingredients may be used independently or in combination.
  • the health supplement food includes health functional food, health food, etc.
  • the health functional food is synonymous with a food for special health use (FoSHU), and refers to a food which has high medical or medicinal effects and which has been processed so that biological regulation functions are efficiently exerted in addition to nutritional supply.
  • “functional” refers to regulating nutrients with respect to structures and functions of a human body or obtaining beneficial effects, such as physiological actions, etc ., which are useful for health use.
  • the food of the present invention can be prepared by a method commonly used in the art. For the preparation of the food, raw materials and ingredients commonly added in the art may be added to the food. In addition, the formulation of the food may be prepared without limitation as long as the formulation is acceptable as a food.
  • the food composition of the present invention may be prepared in various types of formulations. Unlike general drugs, the food composition uses a food as an ingredient, and thus has an advantage in that there are no side effects, etc., which may be caused by long-term intake of a drug, and has excellent portability.
  • Still another aspect of the present invention provides a feed composition for preventing or ameliorating metabolic liver disease, comprising ulixertinib or a sitologically acceptable salt thereof.
  • the term "feed” refers to a substance that supplies organic or inorganic nutrients required for maintaining animal life.
  • the feed may include nutrients for energy, such as proteins, lipids, vitamins, minerals, etc. that are required for animals including livestock, etc., and may be a plant-based feed such as grains, nuts, processed food by-products, seaweed, fiber, fats and oils, starches, meals, grain by-products, etc., or an animal-based feed such as proteins, inorganic matter, fats and oils, minerals, single cell proteins, etc., but the feed is not limited thereto.
  • the feed of the present invention may include a powder feed, a solid feed, a moist pellet feed, a dry pellet feed, an extruder pellet (EP) feed, a raw feed, etc., but is not limited thereto.
  • the feed composition of the present invention may include binders, emulsifiers, preservatives, etc. which can be added to prevent quality deterioration.
  • the feed composition may include a feed additive.
  • the feed additive may include amino acids, vitamins, enzymes, flavoring agents, non-protein nitrogen compounds, silicates, buffers, extracts, oligosaccharides, etc. which are added to a feed to increase utility.
  • the feed additive may further include a feed mixture(s), etc., but is not limited thereto.
  • NASH was established in male mice by a single subcutaneous injection of 200 ⁇ g streptozotocin (STZ, Sigma, USA) 2 days after birth and feeding with a high-fat diet (CLEA Japan Inc., Japan) ad libitum after 4 weeks of age (day 28 ⁇ 2).
  • mice at 6 weeks of age (day 42 ⁇ 2) prepared in Example 1 were randomly divided into 3 groups of 7 or 8 mice.
  • the present inventors selected ulixertinib as a substance expected to have a therapeutic effect on non-alcoholic steatohepatitis through a screening method using artificial intelligence (AI) deep learning technology.
  • AI artificial intelligence
  • the 3 groups of mice were each intraperitoneally injected or orally administered with the following compounds at an amount of about 100 ⁇ L/mouse.
  • the negative control group of ulixertinib in the present invention the vehicle administration group was treated with a solvent of the same amount used for compound dissolution.
  • Telmisartan (Boehringer Ingelheim GmbH, Germany) was used in the positive control group.
  • the telmisartan is a compound which has anti-NASH, anti-fibrosis, and anti-inflammatory effects in NASH and in a liver disease animal model related to NASH.
  • mice were intraperitoneally administered with a vehicle (4% DMSO in saline) at in a volume of 5 mL/kg once daily from 6 weeks to 9 weeks of age.
  • telmisartan administration group positive control group
  • 8 NASH mice were orally administered with purified water supplemented with telmisartan at a dose of 10 mg/kg once daily from 6 weeks to 9 weeks of age.
  • the body weight of each mouse was measured daily during the treatment period, and the survival rate, clinical symptoms, and behaviors of each mouse were monitored daily.
  • mice in Groups 1 to 3 were sacrificed at 9 weeks of age, and the liver was excised therefrom.
  • liver tissue slide For H&E staining, after sectioning liver tissue, a liver tissue slide fixed with paraffin was immersed in a xylene solution for 3 minutes to remove the paraffin. Thereafter, in order to remove the xylene, the liver tissue slide was immersed in ethanol for 3 minutes and then hydrated with distilled water. Subsequently, the liver tissue slide was immersed in a hematoxylin solution for 5 to 10 minutes and then hydrated with distilled water for 5 minutes, followed by quickly immersing it twice in a 1% HCl solution, and then hydrating with distilled water. Then, the liver tissue slide was immersed in a 1% ammonia solution for 2 minutes to stain the tissue blue.
  • liver tissue stained blue was immersed in an eosin solution for 2 minutes, followed by immersing the resultant in ethanol for about 3 to 5 minutes.
  • the liver tissue was immersed in a xylene solution, whereupon the thus-stained liver fragment was observed under a microscope.
  • FIG. 1 The photomicrographs of the liver section stained with H&E, which were observed under a microscope, are as shown in FIG. 1.
  • the liver section of the vehicle administration group exhibited serious fat accumulation, inflammatory cell infiltration, and ballooning which is a phenomenon in which hepatic cells swell.
  • the above pathological conditions of the liver tissue of the ulixertinib administration group were improved compared to those of the vehicle administration group, and that the ulixertinib administration group exhibited an excellent effect compared to the telmisartan administration group ( i.e ., positive control group).
  • the ballooning of hepatic cells was remarkably reduced in the liver tissue of the ulixertinib administration group.
  • the NAFLD activity score (NAS) is a combined value obtained considering each condition of steatosis, inflammation, and ballooning, which are observed in a liver section stained with H&E.
  • the NAFLD score was calculated according to Kleiner's criteria (Kleiner DE et al ., 2005).
  • the composition of an NAFLD activity score is shown in Table 1 below.
  • Steatosis, inflammation, and ballooning scores were determined according to severity of symptoms based on observation in H&E-stained liver sections.
  • inflammation score of the ulixertinib administration group (2.57 ⁇ 0.53) was similar to that of the telmisartan administration group, which is a positive control group (2.5 ⁇ 0.53).
  • the NAFLD activity score in which the steatosis score, inflammatory score, and ballooning score above are comprehensively considered, is shown in FIG. 5.
  • the NAFLD activity score of the vehicle administration group was 4.5 ⁇ 0.53, while that of the telmisartan administration group was 2.63 ⁇ 0.52 ( p ⁇ 0.0001 relative to the vehicle administration group), and that of the ulixertinib administration group had a NAFLD activity score of 3 ⁇ 0.82 ( p ⁇ 0.001 relative to the vehicle administration group). That is, the ulixertinib administration group showed a significant decrease in the NAFLD activity score as compared to the vehicle administration group ( p ⁇ 0.05), and it was similar to the telmisartan administration group ( i.e., positive control group).
  • Sirius red staining is a staining method most frequently used in diagnosis to evaluate the level of tissue destruction, which enables observation of the fibrosis level of inflammation induced by non-alcoholic steatohepatitis.
  • a sirius red reagent was maintained in an equilibrium state and stirred gently. After removing paraffin from a liver tissue section fixed with paraffin, the liver tissue section was hydrated with distilled water and then completely immersed in a sirius red solution for 60 minutes. The liver tissue slide was quickly rinsed twice with an acetic acid solution, followed by rinsing the slide with 100% ethanol. After removing the slide, the liver tissue was mounted with a synthetic resin and then observed under a microscope.
  • a value of a sirius red positive area was determined according to severity of fibrosis development based on observation in sirius red stained liver sections.
  • the fibrosis area score of the vehicle administration group was 0.73 ⁇ 0.12
  • that of the telmisartan administration group i.e., positive control group
  • that of the ulixertinib administration group was 0.35 ⁇ 0.1 ( p ⁇ 0.0001 relative to the vehicle administration group) (FIG. 7).
  • ulixertinib exhibits a significant decrease in the fibrosis area due to inflammation induced by non-alcoholic steatohepatitis, and thus has an effect for treating non-alcoholic fatty liver disease.
  • Example 2 In order to determine a safe oral administration dose of ulixertinib, as in Example 2, the NASH mice in Example 1 were randomly divided into 3 groups of 7 or 8 mice, followed by oral administration with the following compounds at about 100 ⁇ L/mouse.
  • mice 7 NASH mice were orally administered with a vehicle (1% DMSO in saline) in a volume of 10 mL/kg once daily from 6 weeks to 9 weeks of age.
  • vehicle 1% DMSO in saline
  • telmisartan administration group positive control group
  • 8 NASH mice were orally administered with purified water supplemented with telmisartan at a dose of 10 mg/kg (a dose of 10 mL/kg) once daily from 6 weeks to 9 weeks of age.
  • Group 3 (ulixertinib administration group: experimental group): 8 NASH mice were orally administered with a vehicle supplemented with ulixertinib at a dose of 4 mg/kg (in a volume of 10 mL/kg) once daily from 6 weeks to 9 weeks of age.
  • the body weight of each mouse was measured daily during the administration period, and the survival rate, clinical symptoms, and behaviors of each mouse were monitored daily.
  • mice in Groups 1 to 3 of Example 4 were sacrificed at 9 weeks of age, and then H&E staining, NAFLD activity score measurement, and sirius red staining were performed according to the method of Example 3.
  • the NAFLD activity score for liver tissue was estimated according to the method of Example 3-2.
  • the NAFLD activity score in which the steatosis score, inflammatory score, and ballooning score above are comprehensively considered, is shown in FIG. 12.
  • the NAFLD activity score of the vehicle administration group was 4.29 ⁇ 0.49, while that of the telmisartan administration group was 2.25 ⁇ 0.46, and that of the ulixertinib administration group was 3.00 ⁇ 0.76. That is, the ulixertinib administration group showed a significant decrease in the NAFLD activity score as compared to the vehicle administration group.
  • Example 3-4 According to the method of Example 3-4, a percentage of a fibrosis area due to inflammation and a value of a sirius red positive area were each estimated through sirius red staining.
  • the percentage of the fibrosis area of the ulixertinib administration group was reduced as compared to that of the vehicle administration group.
  • the fibrosis area score of the vehicle administration group was 0.69 ⁇ 0.13, while that of the telmisartan administration group (i.e., positive control group) was 0.44 ⁇ 0.06, and that of the ulixertinib administration group was 0.48 ⁇ 0.19, which is similar to that of the telmisartan administration group (FIG. 14).
  • the body weight, liver weight, and liver-to-body weight ratio of the 9-week-old mouse of Example 4 are as shown in FIG. 15.
  • the average liver weight (mg) of the ulixertinib administration group (1577 ⁇ 103 mg) was reduced as compared to that of the vehicle administration group (1776 ⁇ 189 mg).
  • the ulixertinib of the present invention can reduce the liver weight that has increased due to non-alcoholic fatty liver disease.
  • the composition of the present invention which comprises ulixertinib, reduces steatosis, inflammation, and ballooning in liver tissue where non-alcoholic fatty liver has been induced; reduces the level of fibrosis of inflammation induced by non-alcoholic steatohepatitis; and reduces the weight of a liver that has increased due to non-alcoholic fatty liver disease. Accordingly, the composition of the present invention can be effectively used for the prevention or treatment of metabolic liver disease including non-alcoholic fatty liver disease, specifically, non-alcoholic steatohepatitis.

Abstract

La présente invention concerne une composition pharmaceutique permettant de prévenir ou de traiter une stéatose hépatique non alcoolique, comprenant de l'ulixertinib. La composition de la présente invention, qui comprend de l'ulixertinib, réduit une stéatose, une inflammation ou un ballonnement dans un tissu hépatique où une stéatose hépatique non alcoolique a été induite; réduit le niveau de fibrose de l'inflammation induite par la stéatose hépatique non alcoolique; et réduit le poids d'un foie qui a augmenté en raison de la stéatose hépatique non alcoolique. Par conséquent, la composition de la présente invention peut être utilisée pour prévenir ou traiter une maladie hépatique métabolique, y compris une stéatose hépatique non alcoolique.
PCT/KR2020/009862 2019-07-29 2020-07-27 Composition pour la prévention ou le traitement d'une maladie hépatique métabolique WO2021020841A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190091955 2019-07-29
KR10-2019-0091955 2019-07-29

Publications (1)

Publication Number Publication Date
WO2021020841A1 true WO2021020841A1 (fr) 2021-02-04

Family

ID=74228718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/009862 WO2021020841A1 (fr) 2019-07-29 2020-07-27 Composition pour la prévention ou le traitement d'une maladie hépatique métabolique

Country Status (1)

Country Link
WO (1) WO2021020841A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086483A1 (fr) * 2021-11-11 2023-05-19 Sagimet Biosciences Inc. Procédés de prédiction de la réponse au traitement dans une stéatose hépatique non alcoolique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091246A1 (fr) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations
US20060106069A1 (en) * 2004-05-14 2006-05-18 Gabriel Martinez-Botella Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
WO2016123574A1 (fr) * 2015-01-30 2016-08-04 Biomed Valley Discoveries, Inc. Formes cristallines de c21h22ci2n4o2
WO2017017677A1 (fr) * 2015-07-27 2017-02-02 Galmed Research And Development Ltd. Polythérapie pour maladies du foie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091246A1 (fr) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations
US20060106069A1 (en) * 2004-05-14 2006-05-18 Gabriel Martinez-Botella Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
WO2016123574A1 (fr) * 2015-01-30 2016-08-04 Biomed Valley Discoveries, Inc. Formes cristallines de c21h22ci2n4o2
WO2017017677A1 (fr) * 2015-07-27 2017-02-02 Galmed Research And Development Ltd. Polythérapie pour maladies du foie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI EUNO, KIM WON, JOO SAE KYUNG, PARK SUNYOUNG, PARK JEONG HWAN, KANG YUN KYUNG, JIN SO-YOUNG, CHANG MEE SOO: "Expression patterns of STAT3, ERK and estrogen-receptor α are associated with development and histologic severity of hepatic steatosis: a retrospective study", DIAGNOSTIC PATHOLOGY, vol. 13, no. 1, 23, 3 April 2018 (2018-04-03), pages 1 - 9, XP055776864, DOI: 10.1186/s13000-018-0698-8 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086483A1 (fr) * 2021-11-11 2023-05-19 Sagimet Biosciences Inc. Procédés de prédiction de la réponse au traitement dans une stéatose hépatique non alcoolique

Similar Documents

Publication Publication Date Title
WO2020256382A1 (fr) Composition pour la prévention ou le traitement d'une maladie du foie métabolique
WO2018182329A1 (fr) Composition ciblant s1pr4 pour prévenir ou traiter une stéatohépatite non alcoolique
WO2019231220A1 (fr) Utilisation d'un composé thiophène 2,3,5-substitué pour prévenir, atténuer ou traiter des cancers du sein
WO2017171491A1 (fr) Composition pharmaceutique comprenant un extrait de cellules souches pour la prévention ou le traitement d'une maladie inflammatoire
WO2013085224A1 (fr) Formulation de couche mince orale à masquage de goût amer de citrate de sildénafil
WO2021020841A1 (fr) Composition pour la prévention ou le traitement d'une maladie hépatique métabolique
WO2020040432A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies musculaires, contenant un extrait de baie de ginseng en tant que principe actif
WO2020256464A1 (fr) Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production
WO2020256383A1 (fr) Composition pour la prévention ou le traitement d'une maladie hépatique
WO2020022789A1 (fr) Composition pharmaceutique permettant de prévenir, de soulager ou de traiter l'arthrose contenant un dérivé de rhodanine en tant que principe actif
WO2019190069A1 (fr) Composition pour la prévention ou le traitement de maladies associées à un trouble cognitif, contenant du muméfural
WO2016133352A1 (fr) Composition visant à prévenir, soulager ou traiter les maladies métaboliques, contenant de l'amodiaquine en tant que principe actif
WO2021002642A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2018208107A1 (fr) Composition pour atténuer, prévenir ou traiter un trouble du sommeil ou composition pour supprimer la résistance à un agoniste du site de liaison aux benzodiazépines du récepteur gaba-a, ou pour atténuer un effet secondaire d'un agoniste du site de liaison aux benzodiazépines du récepteur gaba-a, chaque composition comprenant du phloroglucinol en tant que principe actif
WO2021261660A1 (fr) Procédé de préparation d'extrait de farine d'huile de sésame et composition alimentaire le comprenant en tant que principe actif pour la prévention ou le soulagement de la colite
WO2020106048A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie neurodégénérative
WO2020055186A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter l'obésité ou la sarcopénie, contenant l'if1 comme principe actif
WO2023027540A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc
WO2021241898A1 (fr) Formulation vétérinaire de film à désintégration orale destinée au traitement ou à la prévention de maladies infectieuses parasitaires chez l'animal
WO2020040522A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies musculaires comprenant un extrait de codonopsis lanceolata en tant que composant efficace
WO2023033535A1 (fr) Composition comprenant un extrait de marron d'inde
WO2023277222A1 (fr) Composition pour la protection du foie comprenant un mélange d'hydrolysat enzymatique et d'hydrolysat acide de placenta de porc
WO2019078381A1 (fr) Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci
WO2021201507A1 (fr) Composition pour prévenir, améliorer ou traiter la sarcopénie, comprenant une protéine de larves de tenebrio molitor ou un hydrolysat de celle-ci en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20847716

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20847716

Country of ref document: EP

Kind code of ref document: A1